{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:02:07Z","timestamp":1789660927247,"version":"4.0.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI165143"],"award-info":[{"award-number":["R01AI165143"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI167003"],"award-info":[{"award-number":["R01AI167003"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1183956"],"award-info":[{"award-number":["OPP1183956"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    HIV broadly neutralizing antibodies (bnAbs) are promising reagents for prevention and therapy of disease; however, their elicitation is constrained by genetic limitations of the human B cell antigen-receptor (BCR) repertoire. Precision genome-editing offers a potential solution by enabling bnAb genes to be programmed into the BCR repertoire as\n                    <jats:italic>IgH<\/jats:italic>\n                    -modified B cells. Such cells can be vaccinated to elicit durable bnAb memory responses in mice; however, extending this success to non-human primates (NHPs) would be a major advance towards clinical translation. Here, we show that ex vivo reprogrammed NHP B cells can survive autologous infusion and respond to immunization, differentiating into antibody-secreting cells (ASCs) that can produce up to 1\u2009\u00b5g\/ml of a bnAb in serum following vaccination prime. Although durable transgenic memory responses were not generated, vaccination of engineered cells in secondary lymphoid organoid (SLO) cultures recapitulated transient ASC responses in vitro. These findings suggest that NHP-derived SLOs could provide a platform to optimize engineering and vaccination conditions that drive germinal center maturation of\n                    <jats:italic>IgH<\/jats:italic>\n                    -reprogrammed B cells in a clinically relevant NHP model, supporting the development of engineered B-cell vaccines that generate durable bnAb responses as a potential functional cure for HIV.\n                  <\/jats:p>","DOI":"10.1038\/s41434-026-00610-8","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:28:57Z","timestamp":1775838537000},"page":"541-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-3932","authenticated-orcid":false,"given":"Mary","family":"Tenuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia L.","family":"Saney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8076-2598","authenticated-orcid":false,"given":"Jason","family":"Weinfurter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana","family":"Ben-Akiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Bhange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-3083","authenticated-orcid":false,"given":"Christopher A.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Vosler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Weisgrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6711-9864","authenticated-orcid":false,"given":"Dennis R.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-1405","authenticated-orcid":false,"given":"Darrell J.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-0150","authenticated-orcid":false,"given":"William R.","family":"Schief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rakasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1367-2829","authenticated-orcid":false,"given":"Chester J.","family":"Joyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-1596","authenticated-orcid":false,"given":"James E.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"610_CR1","doi-asserted-by":"crossref","unstructured":"Sever B, Otsuka M, Fujita M, Ciftci H. A review of FDA-approved anti-HIV-1 drugs, anti-gag compounds, and potential strategies for HIV-1 eradication. Int J Mol Sci. 2024;25:3659.","DOI":"10.3390\/ijms25073659"},{"key":"610_CR2","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","volume":"393","author":"AJ Rodger","year":"2019","unstructured":"Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393:2428\u201338.","journal-title":"Lancet"},{"key":"610_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1126\/science.277.5322.112","volume":"277","author":"B Autran","year":"1997","unstructured":"Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112\u20136.","journal-title":"Science"},{"key":"610_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-59","volume":"6","author":"SD Lawn","year":"2006","unstructured":"Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis. 2006;6:59.","journal-title":"BMC Infect Dis"},{"key":"610_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/387183a0","volume":"387","author":"TW Chun","year":"1997","unstructured":"Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183\u20138.","journal-title":"Nature"},{"key":"610_CR6","doi-asserted-by":"publisher","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","volume":"96","author":"RT Davey Jr.","year":"1999","unstructured":"Davey RT Jr., Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA. 1999;96:15109\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"610_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/00002030-200204120-00009","volume":"16","author":"J Martinez-Picado","year":"2002","unstructured":"Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, Petropoulos CJ, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS. 2002;16:895\u20139.","journal-title":"AIDS"},{"key":"610_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/00002030-200305020-00021","volume":"17","author":"CL Tremblay","year":"2003","unstructured":"Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, et al. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS. 2003;17:1086\u20139.","journal-title":"AIDS"},{"key":"610_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","volume":"7","author":"A Chawla","year":"2018","unstructured":"Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7:183\u201395.","journal-title":"Infect Dis Ther"},{"key":"610_CR10","unstructured":"Cohen J \u2018A bloodbath\u2019;: HIV field is reeling after billions in U.S. funding are axed. Science. 2025."},{"key":"610_CR11","unstructured":"World Health Organization, Prevalence of HIV among adults aged 15-49 (%). WHO Global Health Observatory. 2025."},{"key":"610_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/jamainternmed.2019.7108","volume":"180","author":"NC McCann","year":"2020","unstructured":"McCann NC, Horn TH, Hyle EP, Walensky RP. HIV antiretroviral therapy costs in the United States, 2012-2018. JAMA Intern Med. 2020;180:601\u20133.","journal-title":"JAMA Intern Med"},{"key":"610_CR13","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/S2352-3018(20)30232-0","volume":"8","author":"M Dybul","year":"2021","unstructured":"Dybul M, Attoye T, Baptiste S, Cherutich P, Dabis F, Deeks SG, et al. The case for an HIV cure and how to get there. Lancet HIV. 2021;8:e51\u2013e8.","journal-title":"Lancet HIV"},{"key":"610_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COH.0000000000000600","volume":"15","author":"M Caskey","year":"2020","unstructured":"Caskey M. Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr Opin HIV AIDS. 2020;15:49\u201355.","journal-title":"Curr Opin HIV AIDS"},{"key":"610_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev-med-110118-045506","volume":"71","author":"ST Karuna","year":"2020","unstructured":"Karuna ST, Corey L. Broadly neutralizing antibodies for HIV prevention. Annu Rev Med. 2020;71:329\u201346.","journal-title":"Annu Rev Med"},{"key":"610_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384:1003\u201314.","journal-title":"N Engl J Med"},{"key":"610_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr., Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487\u201391.","journal-title":"Nature"},{"key":"610_CR18","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7:319ra206.","journal-title":"Sci Transl Med"},{"key":"610_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23:185\u201391.","journal-title":"Nat Med"},{"key":"610_CR20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018;24:1701\u20137.","journal-title":"Nat Med"},{"key":"610_CR21","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021;27:1718\u201324.","journal-title":"Nat Med"},{"key":"610_CR22","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med. 2022;28:1288\u201396.","journal-title":"Nat Med"},{"key":"610_CR23","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","volume":"30","author":"B Julg","year":"2024","unstructured":"Julg B, Walker-Sperling VEK, Wagh K, Aid M, Stephenson KE, Zash R, et al. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial. Nat Med. 2024;30:3534\u201343.","journal-title":"Nat Med"},{"key":"610_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler C, Nogueira L, Stoffel E, Oliveira TY, Breton G, Millard KG, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022;606:368\u201374.","journal-title":"Nature"},{"key":"610_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","volume":"606","author":"MC Sneller","year":"2022","unstructured":"Sneller MC, Blazkova J, Justement JS, Shi V, Kennedy BD, Gittens K, et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature. 2022;606:375\u201381.","journal-title":"Nature"},{"key":"610_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh0004","volume":"15","author":"RL Shapiro","year":"2023","unstructured":"Shapiro RL, Ajibola G, Maswabi K, Hughes M, Nelson BS, Niesar A, et al. Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. Sci Transl Med. 2023;15:eadh0004.","journal-title":"Sci Transl Med"},{"key":"610_CR27","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 2016;375:2037\u201350.","journal-title":"N Engl J Med"},{"key":"610_CR28","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","volume":"6","author":"TA Crowell","year":"2019","unstructured":"Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV. 2019;6:e297\u2013e306.","journal-title":"Lancet HIV"},{"key":"610_CR29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535:556\u201360.","journal-title":"Nature"},{"key":"610_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561:479\u201384.","journal-title":"Nature"},{"key":"610_CR31","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016;352:997\u20131001.","journal-title":"Science"},{"key":"610_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","volume":"26","author":"J Niessl","year":"2020","unstructured":"Niessl J, Baxter AE, Mendoza P, Jankovic M, Cohen YZ, Butler AL, et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat Med. 2020;26:222\u20137.","journal-title":"Nat Med"},{"key":"610_CR33","doi-asserted-by":"crossref","unstructured":"Kiani Z, Urbach JM, Wisner H, Olatotse MJ, Chang DY, Acklin JA, et al. CD8(+) T cell stemness precedes post-intervention control of HIV viremia. Nature. 2025;650:196\u2013204.","DOI":"10.1038\/s41586-025-09932-w"},{"key":"610_CR34","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","volume":"34","author":"DR Burton","year":"2016","unstructured":"Burton DR, Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol. 2016;34:635\u201359.","journal-title":"Annu Rev Immunol"},{"key":"610_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734304","volume":"12","author":"M Phelps","year":"2021","unstructured":"Phelps M, Balazs AB. Contribution to HIV prevention and treatment by antibody-mediated effector function and advances in broadly neutralizing antibody delivery by vectored immunoprophylaxis. Front Immunol. 2021;12:734304.","journal-title":"Front Immunol"},{"key":"610_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/COH.0000000000000803","volume":"18","author":"LR Joshi","year":"2023","unstructured":"Joshi LR, Galvez NMS, Ghosh S, Weiner DB, Balazs AB. Delivery platforms for broadly neutralizing antibodies. Curr Opin HIV AIDS. 2023;18:191\u2013208.","journal-title":"Curr Opin HIV AIDS"},{"key":"610_CR37","doi-asserted-by":"crossref","unstructured":"Voss JE, Gonzalez-Martin A, Andrabi R, Fuller RP, Murrell B, McCoy LE, et al. Reprogramming the antigen specificity of B cells using genome-editing technologies. Elife. 2019;8:42995.","DOI":"10.7554\/eLife.42995"},{"key":"610_CR38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1084\/jem.20190287","volume":"216","author":"H Hartweger","year":"2019","unstructured":"Hartweger H, McGuire AT, Horning M, Taylor JJ, Dosenovic P, Yost D, et al. HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells. J Exp Med. 2019;216:1301\u201310.","journal-title":"J Exp Med"},{"key":"610_CR39","doi-asserted-by":"crossref","unstructured":"Moffett HF, Harms CK, Fitzpatrick KS, Tooley MR, Boonyaratanakornkit J, Taylor JJ B cells engineered to express pathogen-specific antibodies protect against infection. Sci Immunol. 2019;4:0644.","DOI":"10.1126\/sciimmunol.aax0644"},{"key":"610_CR40","doi-asserted-by":"crossref","unstructured":"Rogers GL, Huang C, Mathur A, Huang X, Chen HY, Stanten K, et al. Reprogramming human B cells with custom heavy-chain antibodies. Nat Biomed Eng. 2024;8:1700\u201314.","DOI":"10.1038\/s41551-024-01240-4"},{"key":"610_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74005-3","volume":"14","author":"N Ueda","year":"2024","unstructured":"Ueda N, Cahen M, Leonard J, Deleurme L, Dreano S, Sirac C, et al. Single-hit genome editing optimized for maturation in B cells redirects their specificity toward tumor antigens. Sci Rep. 2024;14:22432.","journal-title":"Sci Rep"},{"key":"610_CR42","doi-asserted-by":"crossref","unstructured":"Pan A, Bailey CC, Ou T, Xu J, Liu X, Hu B, et al. In vivo affinity maturation of the HIV-1 Env-binding domain of CD4. Res Sq. 2024:578630.","DOI":"10.1101\/2024.02.03.578630"},{"key":"610_CR43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41551-024-01179-6","volume":"8","author":"Y Yin","year":"2024","unstructured":"Yin Y, Guo Y, Jiang Y, Quinlan B, Peng H, Crynen G, et al. In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nat Biomed Eng. 2024;8:361\u201379.","journal-title":"Nat Biomed Eng"},{"key":"610_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19650-8","volume":"11","author":"D Huang","year":"2020","unstructured":"Huang D, Tran JT, Olson A, Vollbrecht T, Tenuta M, Guryleva MV, et al. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. Nat Commun. 2020;11:5850.","journal-title":"Nat Commun"},{"key":"610_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19649-1","volume":"11","author":"AD Nahmad","year":"2020","unstructured":"Nahmad AD, Raviv Y, Horovitz-Fried M, Sofer I, Akriv T, Nataf D, et al. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nat Commun. 2020;11:5851.","journal-title":"Nat Commun"},{"key":"610_CR46","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","volume":"40","author":"AD Nahmad","year":"2022","unstructured":"Nahmad AD, Lazzarotto CR, Zelikson N, Kustin T, Tenuta M, Huang D, et al. In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nat Biotechnol. 2022;40:1241\u20139.","journal-title":"Nat Biotechnol"},{"key":"610_CR47","doi-asserted-by":"crossref","unstructured":"Li H, Wang S, Lee FH, Roark RS, Murphy AI, Smith J, et al. New SHIVs and improved design strategy for modeling HIV-1 transmission, immunopathogenesis, prevention and cure. J Virol. 2021;95.","DOI":"10.1128\/JVI.00071-21"},{"key":"610_CR48","doi-asserted-by":"crossref","unstructured":"Hartweger H, Gautam R, Nishimura Y, Schmidt F, Yao KH, Escolano A, et al. Gene editing of primary Rhesus Macaque B cells. J Vis Exp. 2023;10:64858.","DOI":"10.3791\/64858"},{"key":"610_CR49","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.04766","volume":"3","author":"S Lin","year":"2014","unstructured":"Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery. Elife. 2014;3:e04766.","journal-title":"Elife"},{"key":"610_CR50","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329:856\u201361.","journal-title":"Science"},{"key":"610_CR51","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1099\/0022-1317-72-11-2727","volume":"72","author":"MD Ryan","year":"1991","unstructured":"Ryan MD, King AM, Thomas GP. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol. 1991;72:2727\u201332.","journal-title":"J Gen Virol"},{"key":"610_CR52","doi-asserted-by":"crossref","unstructured":"Wang Z, Barnes CO, Gautam R, Cetrulo Lorenzi JC, Mayer CT, Oliveira TY, et al. A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. Elife. 2020;9:e61991.","DOI":"10.7554\/eLife.61991"},{"key":"610_CR53","doi-asserted-by":"crossref","unstructured":"Roark RS, Li H, Williams WB, Chug H, Mason RD, Gorman J, et al. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science. 2021;371:2638.","DOI":"10.1126\/science.abd2638"},{"key":"610_CR54","doi-asserted-by":"publisher","first-page":"e1005815","DOI":"10.1371\/journal.ppat.1005815","volume":"12","author":"JG Jardine","year":"2016","unstructured":"Jardine JG, Sok D, Julien JP, Briney B, Sarkar A, Liang CH, et al. Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design. PLoS Pathog. 2016;12:e1005815.","journal-title":"PLoS Pathog"},{"key":"610_CR55","doi-asserted-by":"crossref","unstructured":"Ghosh AR, Habib R, Mishra N, Roark RS, Akauliya M, Albowaidey AA, et al. Rapid acquisition of HIV-1 neutralization breadth in a rhesus V2 apex germline antibody mouse model after a single bolus immunization. bioRXiv. (2025).","DOI":"10.1101\/2025.06.12.659380"},{"key":"610_CR56","doi-asserted-by":"publisher","first-page":"e1007974","DOI":"10.1371\/journal.ppat.1007974","volume":"15","author":"CJ Joyner","year":"2019","unstructured":"Joyner CJ, Brito CFA, Saney CL, Joice Cordy R, Smith ML, Lapp SA, et al. Humoral immunity prevents clinical malaria during Plasmodium relapses without eliminating gametocytes. PLoS Pathog. 2019;15:e1007974.","journal-title":"PLoS Pathog"},{"key":"610_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.602539","volume":"12","author":"A Stewart","year":"2021","unstructured":"Stewart A, Ng JC, Wallis G, Tsioligka V, Fraternali F, Dunn-Walters DK. Single-cell transcriptomic analyses define distinct peripheral b cell subsets and discrete development pathways. Front Immunol. 2021;12:602539.","journal-title":"Front Immunol"},{"key":"610_CR58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41590-024-02010-9","volume":"26","author":"CE Faliti","year":"2025","unstructured":"Faliti CE, Van TTP, Anam FA, Cheedarla N, Williams ME, Mishra AK, et al. Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE. Nat Immunol. 2025;26:131\u201345.","journal-title":"Nat Immunol"},{"key":"610_CR59","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49:725\u201339 e6.","journal-title":"Immunity"},{"key":"610_CR60","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3389\/fimmu.2019.02458","volume":"10","author":"I Sanz","year":"2019","unstructured":"Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front Immunol. 2019;10:2458.","journal-title":"Front Immunol"},{"key":"610_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112682","volume":"42","author":"M Duan","year":"2023","unstructured":"Duan M, Nguyen DC, Joyner CJ, Saney CL, Tipton CM, Andrews J, et al. Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. Cell Rep. 2023;42:112682.","journal-title":"Cell Rep"},{"key":"610_CR62","doi-asserted-by":"crossref","unstructured":"Joyner CJ, Ley AM, Nguyen DC, Ali M, Corrado A, Tipton C, et al. Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting. Life Sci Alliance. 2022;5:e202101285.","DOI":"10.26508\/lsa.202101285"},{"key":"610_CR63","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1126\/science.aat9120","volume":"363","author":"T Tokatlian","year":"2019","unstructured":"Tokatlian T, Read BJ, Jones CA, Kulp DW, Menis S, Chang JYH, et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science. 2019;363:649\u201354.","journal-title":"Science"},{"key":"610_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf1152","volume":"6","author":"M Silva","year":"2021","unstructured":"Silva M, Kato Y, Melo MB, Phung I, Freeman BL, Li Z, et al. A particulate saponin\/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Sci Immunol. 2021;6:eabf1152.","journal-title":"Sci Immunol"},{"key":"610_CR65","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.1234150","volume":"340","author":"J Jardine","year":"2013","unstructured":"Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340:711\u20136.","journal-title":"Science"},{"key":"610_CR66","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1182\/blood-2008-10-185421","volume":"113","author":"J Eckl-Dorna","year":"2009","unstructured":"Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood. 2009;113:3969\u201377.","journal-title":"Blood"},{"key":"610_CR67","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4049\/jimmunol.2001173","volume":"207","author":"D Possamai","year":"2021","unstructured":"Possamai D, Page G, Panes R, Gagnon E, Lapointe R. CD40L-Stimulated B lymphocytes are polarized toward APC functions after exposure to IL-4 and IL-21. J Immunol. 2021;207:77\u201389.","journal-title":"J Immunol"},{"key":"610_CR68","doi-asserted-by":"publisher","first-page":"E6639","DOI":"10.1073\/pnas.1606050113","volume":"113","author":"HH Tam","year":"2016","unstructured":"Tam HH, Melo MB, Kang M, Pelet JM, Ruda VM, Foley MH, et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci USA. 2016;113:E6639\u2013E48.","journal-title":"Proc Natl Acad Sci USA"},{"key":"610_CR69","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41586-022-05216-9","volume":"609","author":"JH Lee","year":"2022","unstructured":"Lee JH, Sutton HJ, Cottrell CA, Phung I, Ozorowski G, Sewall LM, et al. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature. 2022;609:998\u20131004.","journal-title":"Nature"},{"key":"610_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-020-01145-0","volume":"27","author":"LE Wagar","year":"2021","unstructured":"Wagar LE, Salahudeen A, Constantz CM, Wendel BS, Lyons MM, Mallajosyula V, et al. Modeling human adaptive immune responses with tonsil organoids. Nat Med. 2021;27:125\u201335.","journal-title":"Nat Med"},{"key":"610_CR71","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.immuni.2023.06.019","volume":"56","author":"JM Kastenschmidt","year":"2023","unstructured":"Kastenschmidt JM, Sureshchandra S, Jain A, Hernandez-Davies JE, de Assis R, Wagoner ZW, et al. Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. Immunity. 2023;56:1910\u201326.","journal-title":"Immunity"},{"key":"610_CR72","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41577-023-00956-9","volume":"23","author":"LE Wagar","year":"2023","unstructured":"Wagar LE. Human immune organoids: a tool to study vaccine responses. Nat Rev Immunol. 2023;23:699.","journal-title":"Nat Rev Immunol"},{"key":"610_CR73","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2024.12.042","volume":"33","author":"DJ Young","year":"2025","unstructured":"Young DJ, Edwards AJ, Quiroz Caceda KG, Liberzon E, Barrientos J, Hong SG, et al. In vivo tracking of ex-vivo-generated (89)Zr-oxine-labeled plasma cells by PET in a non-human primate model. Mol Ther. 2025;33:580\u201394.","journal-title":"Mol Ther"},{"key":"610_CR74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","volume":"48","author":"RK Abbott","year":"2018","unstructured":"Abbott RK, Lee JH, Menis S, Skog P, Rossi M, Ota T, et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity. 2018;48:133\u201346.","journal-title":"Immunity"},{"key":"610_CR75","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4049\/jimmunol.2100004","volume":"208","author":"E Robinson","year":"2022","unstructured":"Robinson E, Care MA, Walker K, Campbell M, Tooze RM, Doody GM. A system for in vitro generation of mature murine plasma cells uncovers differential blimp-1\/PRDM1 promoter usage. J Immunol. 2022;208:514\u201325.","journal-title":"J Immunol"},{"key":"610_CR76","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42:e168.","journal-title":"Nucleic Acids Res"},{"key":"610_CR77","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1099\/0022-1317-82-5-1027","volume":"82","author":"MLL Donnelly","year":"2001","unstructured":"Donnelly MLL, Hughes LE, Luke G, Mendoza H, Ten Dam E, Gani D, et al. The \u2018cleavage\u2019 activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring \u20182A-like\u2019 sequences. J Gen Virol. 2001;82:1027\u201341.","journal-title":"J Gen Virol"},{"key":"610_CR78","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.immuni.2020.12.018","volume":"54","author":"N Vazquez Bernat","year":"2021","unstructured":"Vazquez Bernat N, Corcoran M, Nowak I, Kaduk M, Castro Dopico X, Narang S, et al. Rhesus and cynomolgus macaque immunoglobulin heavy-chain genotyping yields comprehensive databases of germline VDJ alleles. Immunity. 2021;54:355\u201366.","journal-title":"Immunity"},{"key":"610_CR79","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.1128\/JVI.00210-15","volume":"89","author":"Saunders KO","year":"2015","unstructured":"Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian\/human immunodeficiency virus infection. J Virol. 2015;89:5895\u2013903.","journal-title":"J Virol"},{"key":"610_CR80","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409:131\u201346.","journal-title":"J Immunol Methods"},{"key":"610_CR81","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1128\/JVI.02853-13","volume":"88","author":"A deCamp","year":"2014","unstructured":"deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2014;88:2489\u2013507.","journal-title":"J Virol"},{"key":"610_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pro.4218","volume":"31","author":"PD Thomas","year":"2022","unstructured":"Thomas PD, Ebert D, Muruganujan A, Mushayahama T, Albou LP, Mi H. PANTHER: making genome-scale phylogenetics accessible to all. Protein Sci. 2022;31:8\u201322.","journal-title":"Protein Sci"},{"key":"610_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19:15.","journal-title":"Genome Biol"},{"key":"610_CR84","doi-asserted-by":"crossref","unstructured":"Cheng RY-H, Kreuser S, Dahl N, Honaker Y, Soligalla R, Lopez C, et al. Advancing cell therapies: single-cell profiling, generation, expansion, and gene delivery in Rhesus Macaque plasma B cells. bioRxiv. 2023:2023.10.29.564645.","DOI":"10.1101\/2023.10.29.564645"},{"key":"610_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41695-z","volume":"9","author":"VA Traag","year":"2019","unstructured":"Traag VA, Waltman L, van Eck NJ. From Louvain to Leiden: guaranteeing well-connected communities. Sci Rep. 2019;9:5233.","journal-title":"Sci Rep"},{"key":"610_CR86","doi-asserted-by":"crossref","unstructured":"McInnes L, Healy J. Melville J. Umap: Uniform manifold approximation and projection for dimension reduction. arXiv preprint arXiv:180203426. 2018.","DOI":"10.21105\/joss.00861"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00610-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00610-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00610-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:03:01Z","timestamp":1789657381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00610-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00610-8","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.R.S and C.A.C. are inventors on patent applications regarding immunogens in this manuscript. W.R.S. is an employee and shareholder of Moderna, Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}